National Institute for Health and Care Excellence2d
Consultation on NHS England proposals for a phased launch of obesity injection
Proposals for a phased launch of the obesity injection tirzepatide have been set out, as a consultation begins. NHS England ...
National Institute for Health and Care Excellence2d
Advanced breast cancer: diagnosis and management (Partial update)
For further information on the guideline development process, please see how we develop NICE guidelines ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
The evaluation committee considered evidence submitted by Santen, a review of this submission by the external assessment group (EAG), and responses from stakeholders. See the committee papers for full ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
The 4 technology appraisal committees are standing advisory committees of NICE. This topic was considered by committee D. Committee members are asked to declare any interests in the technology being ...
National Institute for Health and Care Excellence3d
Make your voice heard on a NICE committee
In this episode, we hear from Professor Jonathan Benger, NICE's deputy chief executive and interim director of our Centre for Guidelines. He's joined by Dr Bryony Kendall who is a GP and sits on NICE ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
Section 7 of the National Institute for Health and Care Excellence (Constitution and Functions) and the Health and Social Care Information Centre (Functions) Regulations 2013 requires integrated care ...
National Institute for Health and Care Excellence4d
NICE ready to work with company to address uncertainty in evidence for elacestrant for advanced breast cancer
The draft guidance, which is open for public consultation until 22 October, does not recommend elacestrant for treating oestrogen receptor-positive, human epidermal growth factor receptor 2-negative ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
Latanoprost–netarsudil is recommended as an option for reducing intraocular pressure (IOP) in adults with primary open-angle glaucoma or ocular hypertension when a prostaglandin analogue alone has not ...
National Institute for Health and Care Excellence3d
Latanoprost–netarsudil for previously treated primary open-angle glaucoma or ocular hypertension
Latanoprost–netarsudil (Roclanda, Santen) is indicated 'for the reduction of elevated intraocular pressure (IOP) in adult patients with primary open-angle glaucoma or ocular hypertension for whom ...